A REVIEW: STATUS OF GENETIC MODULATED NONSMALL CELL LUNG CANCER TARGETS AND TREATMENT (CURRENT UPDATES IN DRUGS FOR NON-SMALL CELL LUNG CANCER TREATMENT)
Authors:
Open Access
- 7 August 2018
- journal article
- review article
- Published by Innovare Academic Sciences Pvt Ltd in Asian Journal of Pharmaceutical and Clinical Research
- Vol. 11 (8) , 40-55
Abstract
Genetic modifications or mutations has been a bottleneck for the treatment of cancer; it is widely known to play a vital role in the progression of metastatic level/stage within the nonsmall cell lung cancer (NSCLC). The NSCLC of cancer is responsible for lung cancer lawsuits. In the various genetic mutations related study has been concluded with the various genes findings, which are named as the epidermal growth factor receptor, anaplastic lymphoma kinase, Kristen rat sarcoma virus, ROS proto-oncogene 1, human epidermal growth factor, B-RAF proto-oncogene, rearranged during Transfection, MET, Phosphatidyl 3-kinases CA, IGF-1R, NTRK1, FGFR1, and DDR2. The various research data supported this study. The involvement of the gene in the NSCLC patients made a paradigm shift in the drug discovery. The presence of one mutation in connection with some other could have an impact on NSCLC remedy.Utilizing this genotype-directed therapy for an advanced NSCLC has to turn out to be an appealing and efficacious treatment strategy. Here in the advancement of research, related genetic modulated targets and treatment have been discussed, particular genetic mutations help to find new updated interventions or medicinal drugs for the treatment of NSCLC. In there view, we have comprehensively arranged the mutation type and treatment with the status of NSCLC.Keywords
This publication has 44 references indexed in Scilit:
- The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future DirectionsTargeted Oncology, 2017
- Clinicopathologic characteristics and outcomes of Chinese patients with non‐small‐cell lung cancer and BRAF mutationCancer Medicine, 2017
- Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitorsFrontiers of Medicine, 2016
- Testing for ROS1 in non-small cell lung cancer: a review with recommendationsVirchows Archiv, 2016
- BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?Critical Reviews in Oncology/Hematology, 2016
- Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancerLung Cancer, 2016
- Prognostic and predictive biomarkers in lung cancer. A reviewVirchows Archiv, 2014
- New Treatment Options for Lung Adenocarcinoma - in View of Molecular BackgroundPathology and Oncology Research, 2013
- KRAS Mutations in Lung CancerClinical Lung Cancer, 2013
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 studyThe Lancet Oncology, 2013